Are photosensitizing medications associated with increased risk of important erythemal reactions during ultraviolet B phototherapy? | Zendy

Harrop G. | Zendy; Dawe R.S. | Zendy; Ibbotson S. | Zendy

Premium

Are photosensitizing medications associated with increased risk of important erythemal reactions during ultraviolet B phototherapy?

Author(s) -

Harrop G.,

Dawe R.S.,

Ibbotson S.

Publication year - 2018

Publication title -

british journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.304

H-Index - 179

eISSN - 1365-2133

pISSN - 0007-0963

DOI - 10.1111/bjd.16800

Subject(s) - medicine , ultraviolet a , ultraviolet , ultraviolet radiation , dermatology , chemistry , materials science , optoelectronics , radiochemistry

Erythemal episodes during phototherapy can be painful, limit efficacy due to premature discontinuation of treatment and may contribute to chronic cutaneous damage. Many patients receiving phototherapy take photosensitive medications. Stern et al., investigated 1,125 patients receiving maintenance psoralen-ultraviolet A photochemotherapy (PUVA) for psoriasis and did not detect a significant difference in risk of erythemal episodes between those receiving photosensitising medication compared with those who were not1 . However, amongst older (≥45 years-old) users of photoactive drugs, 10% discontinued PUVA for at least a month because of "burns" compared with only 5% on "non-users". This article is protected by copyright. All rights reserved.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research